Hero

Celyad Reports First Half 2016 Financial Results and Operational Progress

1

Celyad Reports First Half 2016 Financial Results and Operational Progress

Developing breakthrough pioneering therapies for life-threatening diseases

2

Developing breakthrough pioneering therapies for life-threatening diseases

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

3

Directing a weaponized attack on cancer with the NKR-T cell immunotherapy

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD

4

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD

About Celyad

Driven by a passion to invent

Celyad is a clinical-stage biopharmaceutical company focused on the discovery and development of breakthrough pioneering cell-based therapies for life-threatening diseases.

More info about Celyad

Latest News

Celyad Letter for Shareholders

Celyad Letter for Shareholders

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial

Celyad Reports First Half 2016 Financial Results and Operational Progress

Celyad Reports First Half 2016 Financial Results and Operational Progress

Discover all news

Social Feed

RT @escardio: #CHART-1 tested efficacy of #cardiopoietic cells in advanced ischaemic #heartfailure - Jozef Bartunek #ESCcongress

5 hours ago

RT @escardio: #CHART-1 tested efficacy of #cardiopoietic cells in advanced ischaemic #heartfailure - Jozef Bartunek #ESCcongress

RT @escardio: #CHART-1 suggests #cardiopoietic cells may benefit patients with larger ventricles and fewer injections - Jozef Bartunek #ESC…

5 hours ago

RT @escardio: #CHART-1 suggests #cardiopoietic cells may benefit patients with larger ventricles and fewer injections - Jozef Bartunek #ESC…

#ESCCongress CHART-1 LARGEST CARDIAC REGENERATIVE THERAPY TRIAL BRINGS NEW INSIGHTS https://t.co/7s3YQstrEd #PressRelease

5 hours ago

#ESCCongress CHART-1 LARGEST CARDIAC REGENERATIVE THERAPY TRIAL BRINGS NEW INSIGHTS https://t.co/7s3YQstrEd #PressRelease

“Within a well-defined patient population, based on baseline heart failure severity, this therapy showed benefit,” said Prof. Jozef Bartunek

5 hours ago

“Within a well-defined patient population, based on baseline heart failure severity, this therapy showed benefit,” said Prof. Jozef Bartunek

RT @escardio: #CHART-1 tested efficacy of #cardiopoietic cells in advanced ischaemic #heartfailure - Jozef Bartunek #ESCcongress

5 hours ago

RT @escardio: #CHART-1 tested efficacy of #cardiopoietic cells in advanced ischaemic #heartfailure - Jozef Bartunek #ESCcongress

RT @escardio: #CHART-1 suggests #cardiopoietic cells may benefit patients with larger ventricles and fewer injections - Jozef Bartunek #ESC…

5 hours ago

RT @escardio: #CHART-1 suggests #cardiopoietic cells may benefit patients with larger ventricles and fewer injections - Jozef Bartunek #ESC…

#ESCCongress CHART-1 LARGEST CARDIAC REGENERATIVE THERAPY TRIAL BRINGS NEW INSIGHTS https://t.co/7s3YQstrEd #PressRelease

5 hours ago

#ESCCongress CHART-1 LARGEST CARDIAC REGENERATIVE THERAPY TRIAL BRINGS NEW INSIGHTS https://t.co/7s3YQstrEd #PressRelease

“Within a well-defined patient population, based on baseline heart failure severity, this therapy showed benefit,” said Prof. Jozef Bartunek

5 hours ago

“Within a well-defined patient population, based on baseline heart failure severity, this therapy showed benefit,” said Prof. Jozef Bartunek

CHART-1 Largest Cardiac Regenerative Therapy Trial Brings New Insights

5 hours ago

CHART-1 Largest Cardiac Regenerative Therapy Trial Brings New Insights

Celyad Reports First Half 2016 Financial Results and Operational Progress

3 days ago

Celyad Reports First Half 2016 Financial Results and Operational Progress

Celyad launches its new website!

2 weeks ago

Celyad launches its new website!

Celyad is hiring an External Innovation Development Manager (US)

2 weeks ago

Celyad is hiring an External Innovation Development Manager (US)